Artivion, Inc. Files Definitive Proxy Statement

Ticker: AORT · Form: DEF 14A · Filed: Apr 1, 2024 · CIK: 784199

Artivion, Inc. DEF 14A Filing Summary
FieldDetail
CompanyArtivion, Inc. (AORT)
Form TypeDEF 14A
Filed DateApr 1, 2024
Risk Levellow
Pages16
Reading Time19 min
Sentimentneutral

Sentiment: neutral

Topics: Proxy Statement, Executive Compensation, Artivion, DEF 14A, Shareholder Voting

TL;DR

<b>Artivion, Inc. has filed its Definitive Proxy Statement detailing executive compensation and award values for fiscal years 2020-2023.</b>

AI Summary

ARTIVION, INC. (AORT) filed a Proxy Statement (DEF 14A) with the SEC on April 1, 2024. Artivion, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024. The filing covers the fiscal year ending December 31, 2023. It includes executive compensation data for PEO and Non-PEO members. Details on stock and option award values are provided for 2023, 2022, 2021, and 2020. The company was formerly known as Cryolife Inc., with a name change in 1994.

Why It Matters

For investors and stakeholders tracking ARTIVION, INC., this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation, allowing them to make informed voting decisions on related proposals. The detailed breakdown of stock and option awards offers insight into how the company incentivizes its leadership and aligns their interests with shareholder value.

Risk Assessment

Risk Level: low — ARTIVION, INC. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational events.

Analyst Insight

Review the executive compensation details and voting proposals in the DEF 14A to understand management's incentives and make informed voting decisions.

Key Numbers

  • 2024-04-01 — Filing Date (DEF 14A filing date)
  • 2023-12-31 — Fiscal Year End (Reporting period)
  • 1994-05-26 — Name Change Date (Former company name date)

Key Players & Entities

  • ARTIVION, INC. (company) — Filer
  • Cryolife Inc. (company) — Former company name

FAQ

When did ARTIVION, INC. file this DEF 14A?

ARTIVION, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 1, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ARTIVION, INC. (AORT).

Where can I read the original DEF 14A filing from ARTIVION, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ARTIVION, INC..

What are the key takeaways from ARTIVION, INC.'s DEF 14A?

ARTIVION, INC. filed this DEF 14A on April 1, 2024. Key takeaways: Artivion, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 1, 2024.. The filing covers the fiscal year ending December 31, 2023.. It includes executive compensation data for PEO and Non-PEO members..

Is ARTIVION, INC. a risky investment based on this filing?

Based on this DEF 14A, ARTIVION, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, which is standard for public companies and does not indicate any unusual financial or operational events.

What should investors do after reading ARTIVION, INC.'s DEF 14A?

Review the executive compensation details and voting proposals in the DEF 14A to understand management's incentives and make informed voting decisions. The overall sentiment from this filing is neutral.

How does ARTIVION, INC. compare to its industry peers?

Artivion, Inc. operates in the medical device industry, specifically focusing on surgical and medical instruments and apparatus.

Are there regulatory concerns for ARTIVION, INC.?

As a publicly traded company, Artivion, Inc. is subject to SEC regulations and filing requirements, including the DEF 14A for proxy solicitations.

Industry Context

Artivion, Inc. operates in the medical device industry, specifically focusing on surgical and medical instruments and apparatus.

Regulatory Implications

As a publicly traded company, Artivion, Inc. is subject to SEC regulations and filing requirements, including the DEF 14A for proxy solicitations.

What Investors Should Do

  1. Analyze the executive compensation structure and any proposed resolutions.
  2. Compare executive compensation trends with industry peers.
  3. Assess the company's historical stock and option award performance.

Key Dates

  • 2024-04-01: Filing of DEF 14A — Provides details on executive compensation and shareholder proposals for the fiscal year ending 2023.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for annual shareholder meetings and does not represent a change from previous filings of the same type.

Filing Stats: 4,805 words · 19 min read · ~16 pages · Grade level 12.6 · Accepted 2024-04-01 16:56:33

Filing Documents

From the Filing

Proxy UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 ARTIVION, INC. (Name of Registrant as Specified In Its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Notice of Annual Meeting and Proxy Statement 2024 Annual Meeting of Stockholders May 14, 2024 ARTIVION, INC. | 2024 Proxy Statement 1655 ROBERTS BOULEVARD, NW KENNESAW, GEORGIA 30144 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT April 1, 2024 To Our Stockholders: On behalf of the Board of Directors, we invite you to attend the Annual Meeting of Stockholders of Artivion, Inc. on May 14 , 2024 at 9:00 a.m., ET. Given our successful use of the virtual-only format at our last four annual meetings, we have again adopted a virtual-only format for our Annual Meeting this year. The Annual Meeting will be accessible at the following website address: https://web.lumiconnect.com/295739807 . After this year's Annual Meeting, we intend to again evaluate the best method for holding our annual stockholder meetings going forward. Please review this Notice of Annual Meeting and Proxy Statement, which describes the formal business to be transacted and procedures for voting on matters to be considered during the Annual Meeting. YO UR VOTE IS IMPORTANT. Regardless of whether you plan to attend the virtual Annual Meeting, we request that you please take a few minutes and follow the instructions provided on the Notice or Proxy Card that you received by mail, and further described herein, to review the Proxy Statement and vote your shares via internet, telephone, or mail. You may, of course, choose to attend the Annual Meeting virtually and vote your shares online during the meeting. If you wish to participate in the meeting, you will need your control number to join. However you choose to participate, we encourage you to review this Proxy Statement and vote your shares. Sincerely, J. PATRICK MACKIN Chairman, President, and Chief Executive Officer ARTIVION, INC. | 2024 Proxy Statement 1655 ROBERTS BOULEVARD, NW KENNESAW, GEORGIA 30144 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO THE STOCKHOLDERS OF ARTIVION, INC.: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of ARTIVION, INC. (the "Annual Meeting") will be held on May 14, 2024 at 9:00 a.m., ET. As in the last four years, the Annual Meeting will be held as a virtual-only meeting. The Annual Meeting will be accessible at the following website address: https://web.lumiconnect.com/295739807 , for the following purposes: 1. To elect as directors the nine nominees named in the attached Proxy Statement to serve until the next Annual Meeting of Stockholders or until their successors are duly qualified or until their earlier death, resignation, or removal. 2. To approve, by non-binding vote, the compensation paid to Artivion's Named Executive Officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion. 3. To ratify the preliminary approval of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024. 4. To approve the amendment and restatement of Artivion's Certificate of Incorporation to allow for officer exculpation as provided for under Delaware law. 5. To transact such other business as may be properly brought before the Annual Meeting or any adjournments thereof. Only record holders of Artiv ion's common stock at the close of business on March 18, 2024 will be eligible to vote during the Annual Meeting. Artivion would like for you to attend the Annual Meeting. However, if there is any chance you may not be able to attend the Annual Meeting, please follow the instructions on the Notice or Proxy Card you received by mail to vote via internet, telephone, or mail. Important notice regarding the availability of proxy materials for the Annual Meeting of Stockholders to be held on May 14 , 2024. Pursuant to the rules promulgated by the Securities and Exchange Commission, we have elected to provide access to our proxy materials by notifying you of the availability of our proxy materials, including the Annual Meeting notice, Proxy Statement, and our 2023 Annual Report to Stockh

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.